Get the Stockscreener App
2.455
2.51%
0.065
After Hours:
2.47
0.015
+0.61%
Moleculin Biotech Inc stock is traded at $2.455, with a volume of 253.59K.
It is up +2.51% in the last 24 hours and down -3.54% over the past month.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
See More
Previous Close:
$2.39
Open:
$2.42
24h Volume:
253.59K
Relative Volume:
1.58
Market Cap:
$13.13M
Revenue:
-
Net Income/Loss:
$-23.92M
P/E Ratio:
-0.0975
EPS:
-25.1834
Net Cash Flow:
$-22.74M
1W Performance:
+4.26%
1M Performance:
-3.54%
6M Performance:
-65.00%
1Y Performance:
-89.70%
1-Day Range:
$2.35
$2.49
1-Week Range:
$2.28
$2.49
52-Week Range:
$1.79
$24.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.46 | 12.75M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech, Inc. Files SEC Form 8-K and Releases May 2026 Investor Presentation - Minichart
Moleculin Biotech (NASDAQ: MBRX) posts new May 2026 investor presentation - Stock Titan
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Annamycin cardiac safety data at ASCO 2026 for Moleculin (NASDAQ: MBRX) - Stock Titan
Moleculin presents cardiac safety data for Annamycin at ASCO By Investing.com - Investing.com South Africa
Moleculin's Annamycin shows no heart toxicity in trials, advancing AML cancer treatment. - Pluang
Moleculin presents cardiac safety data for Annamycin at ASCO - Investing.com
Pooled trials of cancer drug Annamycin find no cardiotoxicity signal - Stock Titan
Nano-cap Moleculin Biotech approaches key leukemia trial data unblinding - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech stock (US60855L2034): Maxim Group keeps Buy rating - AD HOC NEWS
Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX - Moomoo
Why did MBRX stock climb 14% today? - MSN
Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX - Moomoo
What Does GF Score 27/100 Say About Moleculin Biotech (MBRX) Aft - GuruFocus
Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Q1 2026 Financial Results and Clinical Trial Updates - Minichart
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech Q1 net loss widens as R&D costs rise - TradingView
Moleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission Rate - Quiver Quantitative
MBRX: Pivotal AML trial hits key enrollment, 40% remission rate; Q1 net loss $12.8M, cash runway into Q3 - TradingView
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Moleculin (NASDAQ: MBRX) Q1 2026 loss deepens while MIRACLE AML trial progresses - Stock Titan
Leukemia trial shows 40% remissions; first MIRACLE data unblinding due June 2026 - Stock Titan
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MBRX: Annamycin advanced in pivotal AML trial; net loss widened, and more funding is needed for operations - TradingView
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moleculin Biotech (MBRX) widens Q1 loss and flags funding gap for MIRACLE trial - Stock Titan
Moleculin reports preliminary data from AML trial ahead of unblinding - Investing.com UK
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding - Yahoo Finance
Moleculin Biotech (MBRX) Approaches Key Data Release in AML Tria - GuruFocus
Moleculin Biotech, Inc. Files Form 8-K for May 13, 2026 – Company Details, Stock Info, and Regulatory Disclosures - Minichart
Moleculin Biotech Incto unblind Miracle trial data before June 30, 2026SEC filing - marketscreener.com
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial - TipRanks
Moleculin reports preliminary data from AML trial ahead of unblinding By Investing.com - Investing.com South Africa
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks - The Manila Times
Moleculin Approaching First MIRACLE Trial Unblinding; Preliminary CR ~30% vs 17–18% SOC - TradingView
Moleculin (NASDAQ: MBRX) posts higher blinded AML remission rates vs cytarabine - Stock Titan
Leukemia study nears June data reveal after early 30% remission rate - Stock Titan
Moleculin Biotech (MBRX) Highlights Annamycin's Cardiac Safety P - GuruFocus
Number of shareholders of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Moleculin Biotech, Inc. Files 8-K Report with SEC – Company and Stock Information as of May 12, 2026 - Minichart
Moleculin highlights favorable cardiac safety data for Annamycin - TipRanks
Moleculin reports cardiac safety data for Annamycin in AML study By Investing.com - Investing.com South Africa
Moleculin reports cardiac safety data for Annamycin in AML study - Investing.com
Moleculin Biotech, Inc. Publishes Positive Cardiac Safety Data for Annamycin in Relapsed/Refractory AML at EHA 2026 Congress - Quiver Quantitative
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits - The Manila Times
Independent Cleveland Clinic review finds no significant cardiotoxicity with Moleculin's Annamycin - TradingView
Cardiac data support Moleculin (NASDAQ: MBRX) Annamycin use in R/R AML - Stock Titan
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):